DOCSLIB.ORG

Atc Index 2009

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Atc Index 2009 ATC INDEX 2009 This is a version of the World Health Organization (WHO) ATC index and, as such, contains some substances for which data are not available in the two tables. This ATC index is sorted alphabetically according to generic/substance International Nonproprietary Name (INN). There may be some variance in the spelling of the generic name. 291 A C 01 E B 10 Adenosine A 03 A B 16 (2-benzhydryloxyethyl) N 05 B A 07 Adinazolam diethyl-methylammonium iodide V 08 A C 04 Adipiodone D 01 A E 06 2-(4-chlorphenoxy)- ethanol N 06 B X 17 Adrafinil V 03 A B 27 4-dimethylaminophenol A 01 A D 06 Adrenalone J 05 A F 06 Abacavir B 02 B C 05 Adrenalone L 02 B X 01 Abarelix L 04 A B 03 Afelimomab L 04 A A 24 Abatacept A 16 A B 03 Agalsidase alfa B 01 A C 13 Abciximab A 16 A B 04 Agalsidase beta L 04 A A 22 Abetimus N 06 A X 22 Agomelatine B 02 B C 01 Absorbable gelatin sponge C 01 B A 05 Ajmaline C 01 E B 13 Acadesine B 05 X B 02 Alanyl glutamine N 07 B B 03 Acamprosate N 06 A B 07 Alaproclate A 10 B F 01 Acarbose P 02 C A 03 Albendazole C 07 A B 04 Acebutolol B 05 A A 01 Albumin C 07 B B 04 Acebutolol and thiazides A 07 X A 01 Albumin tannate S 01 E B 08 Aceclidine A 07 X A 51 Albumin tannate, combinations S 01 E B 58 Aceclidine, combinations M 01 A B 06 Alclofenac M 01 A B 16 Aceclofenac D 07 A B 10 Alclometasone M 02 A A 25 Aceclofenac S 01 B A 10 Alclometasone R 03 D A 09 Acefylline piperazine M 03 A A 01 Alcuronium M 01 A B 11 Acemetacin L 03 A C 01 Aldesleukin B 01 A A 07 Acenocoumarol J 04 B A 03 Aldesulfone sodium N 05 A A 04 Acepromazine H 02 A A 01 Aldosterone A 07 A X 02 Acetarsol L 04 A A 15 Alefacept G 01 A B 01 Acetarsol L 01 X C 04 Alemtuzumab P 01 C D 02 Acetarsol M 05 B A 04 Alendronic acid S 01 E C 01 Acetazolamide M 05 B B 03 Alendronic acid and colecalciferol G 01 A D 02 Acetic Acid B 02 A B 02 Alfal antitrypsin S 02 A A 10 Acetic Acid A 11 C C 03 Alfacalcidol A 10 B B 31 Acetohexamide N 01 A X 05 Alfaxalone G 04 B X 03 Acetohydroxamic acid N 01 A H 02 Alfentanil N 05 A B 07 Acetophenazine G 04 C A 01 Alfuzosin A 02 B X 09 Acetoxolone A 02 A B 02 Algeldrate V 08 A A 07 Acetrizoic acid A 02 B X 13 Alginic acid N 06 B X 12 Acetylcarnitine A 16 A B 01 Alglucerase S 01 E B 09 Acetylcholine A 16 A B 07 Alglucosidase alfa R 05 C B 01 Acetylcysteine R 06 A D 01 Alimemazine S 01 X A 08 Acetylcysteine C 10 A X 10 Alipogene tiparvovec V 03 A B 23 Acetylcysteine C 09 X A 02 Aliskiren C 01 A A 01 Acetyldigitoxin C 09 X A 52 Aliskiren and hydrochlorothiazide C 01 A A 02 Acetyldigoxin D 11 A X 19 Alitretinoin C 01 A A 52 Acetyldigoxin, combinations L 01 X X 22 Alitretinoin R 05 D A 12 Acetyldihydrocodeine A 03 F A 05 Alizapride N 05 C C 03 Acetylglycinamide chloral hydrate N 05 C A 21 Allobarbital N 07 C A 04 Acetylleucine M 04 A A 01 Allopurinol A 01 A D 05 Acetylsalicylic acid M 04 A A 51 Allopurinol, combinations B 01 A C 06 Acetylsalicylic acid G 03 D C 01 Allylestrenol N 02 B A 01 Acetylsalicylic acid A 02 A D 03 Almagate M 01 B A 03 Acetylsalicylic acid and corticosteroids A 02 A D 03 Almasilate N 02 B A 51 Acetylsalicylic acid, comb. excl. psycholeptics M 01 A E 16 Alminoprofen N 02 B A 71 Acetylsalicylic acid, comb. with psycholeptics R 07 A B 07 Almitrine D 06 B B 03 Aciclovir N 02 C C 05 Almotriptan J 05 A B 01 Aciclovir A 02 A B 06 Aloglutamol S 01 A D 03 Aciclovir A 03 A E 01 Alosetron C 10 A D 06 Acipimox B 01 A C 15 Aloxiprin D 05 B B 02 Acitretinz N 02 B A 02 Aloxiprin L 01 D B 04 Aclarubicin N 05 B A 12 Alprazolam R 02 A A 13 Acriflavinium chloride C 07 A A 01 Alprenolol R 06 A X 18 Acrivastine C 01 E A 01 Alprostadil L 04 A B 04 Adalimumab G 04 B E 01 Alprostadil D 10 A D 03 Adapalene V 04 C H 04 Alsactide D 10 A D 53 Adapalene, combinations B 01 A D 02 Alteplase J 05 A F 08 Adefovir dipivoxil S 01 X A 13 Alteplase A 16 A A 02 Ademetionine R 05 C A 05 Althea root 292 C 03 E A 04 Altizide and potassium-sparing agents J 01 C A 04 Amoxycillin L 01 X X 03 Altretamine J 01 C R 02 Amoxycillin and enzyme inhibitor S 01 X A 07 Alum A 01 A B 04 Amphotericin B A 02 A B 05 Aluminium acetoacetate A 07 A A 07 Amphotericin B S 02 A A 04 Aluminium acetotartrate G 01 A A 03 Amphotericin B D 10 A X 01 Aluminium chloride J 02 A A 01 Amphotericin B D 09 A A 08 Aluminium Chlorohydrate J 01 C A 01 Ampicillin M 05 B X 02 Aluminium Chlorohydrate S 01 A A 19 Ampicillin C 10 A B 03 Aluminium clofibrate J 01 C R 01 Ampicillin and enzyme inhibitor A 02 A B 07 Aluminium glycinate J 01 C A 51 Ampicillin, combinations A 02 A B 01 Aluminium hydroxide J 05 A E 05 Amprenavir C 10 A D 04 Aluminium nicotinate C 01 C E 01 Amrinone D 10 A X 04 Aluminium oxide L 01 X X 01 Amsacrine A 02 A B 03 Aluminium phosphate V 03 A B 22 Amyl nitrite C 05 A X 01 Aluminium preparations L 01 X X 35 Anagrelide A 03 A X 08 Alverine L 04 A C 03 Anakinra A 03 A X 58 Alverine, combinations S 02 D A Analgesics and anesthetics N 04 B B 01 Amantadine L 02 B G 03 Anastrozole R 02 A A 01 Ambazone L 03 A A 12 Ancestim N 07 A A 30 Ambenonium B 01 A D 09 Ancrod C 02 K X 02 Ambriesentan A 14 A A 01 Androstanolone R 05 C B 06 Ambroxol G 03 B B 02 Androstanolone A 03 C A 07 Ambutonium and psychleptics S 01 X A 16 Anecortave D 07 A C 11 Amcinonide A 16 A X 02 Anethole trithione A 08 A A 03 Amfepramone C 09 D B Angiotensin II anatagoinsts and calcium N 06 B A 01 Amfetamine channel blockers N 07 X X 05 Amifampridine C 01 C X 06 Angiotensinamide V 03 A F 05 Amifostine J 02 A X 06 Anidulafungin D 06 A X 12 Amikacin N 01 A H 05 Anileridine J 01 G B 06 Amikacin V 01 A A 11 Animals S 01 A A 21 Amikacin N 06 B X 11 Aniracetam C 03 D B 01 Amiloride B 01 A D 03 Anistreplase N 06 A A 19 Amineptine A 02 A X Antacids, other combinations B 05 B A 01 Amino acids R 01 A C 04 Antazoline N 03 A B 03 Amino (diphenylhydantoin) valeric acid R 06 A X 05 Antazoline D 08 A A 02 Aminoacridine J 07 A C 01 Anthrax antigen D 02 B A 01 Aminobenzoic acid D 06 A X Antibiotics for topical use, other N 03 A G 03 Aminobutyric acid S 01 A A 20 Antibiotics in combination with other drugs B 02 A A 01 Aminocaproic acid J 06 B B 01 Anti-D (Rh) immunoglobulin L 02 B G 01 Aminogluthetimide A 02 D A Antiflatulents V 04 C H 30 Aminohippuric acid D 11 A A Antihidrotics L 01 X D 04 Aminolevulinic acid S 03 A A Antiinfectives B 02 A A 03 Aminomethylbenzoic acid S 02 A A 30 Antiinfectives, combinations N 02 B B 03 Aminophenazone S 03 A A 30 Antiinfectives, combinations N 02 B B 53 Aminophenazone, combinations excl. L 04 A A 03 Antilymphocyte immunoglobulin (horse) psycholeptics R 05 C A 07 Antimony pentasulfide N 02 B B 73 Aminophenazone, combinations with D 04 A X Antipruritics, other psycholeptics B 01 A B 02 Antithrombin III R 03 D A 05 Aminophylline L 04 A A 04 Antithymocyte immunoglobulin (rabbit) R 03 D B 05 Aminophylline and adrenergics G 04 B E 07 Apomorphine R 03 D A 55 Aminophylline, combinations N 04 B C 07 Apomorphine J 04 A A 01 Aminosalicylic acid S 01 E A 03 Apraclonidine C 01 B D 01 Amiodarone A 04 A D 12 Aprepitant N 05 A L 05 Amisulpride C 01 B B 04 Aprindine N 06 A A 09 Amitriptyline N 05 C A 05 Aprobarbital N 06 C A 01 Amitriptyline and psycholeptics N 05 C M 12 Apronal A 01 A D 07 Amlexanox B 02 A B 01 Aprotinin R 03 D X 01 Amlexanox J 01 G B 12 Arbekacin C 08 C A 01 Amlodipine C 01 C A 22 Arbutamine B 05 X A 04 Ammonium chloride B 01 A E 03 Argatroban G 04 B A 01 Ammonium chloride A 05 B A 01 Arginine glutamate N 05 C A 02 Amobarbital B 05 X B 01 Arginine hydrochloride P 01 B A 06 Amodiaquine H 01 B A 06 Argipressin D 01 A E 16 Amorolfine N 05 A X 12 Aripiprazole N 06 A A 17 Amoxapine L 01 X X 27 Arsenic trioxide 293 P 01 A R 01 Arsthinol R 03 D A 08 Bamifylline P 01 B E 02 Artemether D 04 A A 15 Bamipine P 01 B E 52 Artemether, combinations R 06 A X 01 Bamipine P 01 B E 01 Artemisinin N 03 A A 04 Barbexaclone P 01 B E 04 Artemotil N 05 C A 04 Barbital P 01 B E 05 Artenimol N 05 C B 02 Barbituates in combination with other drugs P 01 B E 03 Artesunate V 08 B A 01 Barium sulphate with suspending agents N 01 B B 08 Articaine V 08 B A 02 Barium sulphate without suspending agents N 01 B B 58 Articaine, combinations C 08 C A 12 Barnidipine S 01 X A 20 Artificial tears and other indifferent preparations L 04 A C 02 Basiliximab G 01 A D 03 Ascorbic acid B 02 B X 03 Batroxobin S 01 X A 15 Ascorbic acid L 03 A X 03 BCG vaccine A 11 G A 01 Ascorbic acid (vit C) D 03 A X 06 Becaplermin A 11 G B 01 Ascorbic acid (vit C) and calcium N 03 A X 30 Beclamide L 01 X X 02 Asparaginase A 07 E A 07 Beclometasone R 06 A X 11 Astemizole D 07 A C 15 Beclometasone J 05 A E 08 Atazanavir R 01 A D 01 Beclometasone C 07 A B 03 Atenolol R 03 B A 01 Beclometasone C 07 F B 03 Atenolol and other hypertensives D 07 C C 04 Beclometasone and antibiotics C 07 C B 03 Atenolol and other diuretics S 01 E D 06 Befunolol C 07 C B 53 Atenolol and other diuretics, combinations A 03 B B Belladonna alkaloids, semisynthetic quarter C 07 B B 03 Atenolol and thiazides amonium compounds C 07 D B 01 Atenolol, thiazides and other diuretics A 03 B A Belladonna alkaloids, tertiary amines N 06 B A 09 Atomoxetine A 03 B A 04 Belladonna total alkaloids C 10 A A 05 Atorvastatin A 03 C B 02 Belladonna total alkaloids and psychleptics C 10 B X 03 Atorvastatin and amlodipine R 07 A B 05 Bemegride G 02 C X 01 Atosiban B 01 A B 12 Bemiparin P 01 A X 06 Atovaquone C 09 A A 07 Benazepril M 03 A C 04 Atracurium C 09 B A 07 Benazepril and diuretics A 03 B A 01 Atropine C 04 A X 11 Bencyclane S 01 F A 01 Atropine M 02 A A 11 Bendazac A 03 C B 03 Atropine and psycholeptics S 01 B C 07 Bendazac A 07 B C 04 Attapulgite C 03 A A 01 Bendroflumethiazide A 07 B C 54 Attapulgite,
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • Par Drugs and Chemicals Limited
    +91-8048372739 PAR DRUGS AND CHEMICALS LIMITED https://www.indiamart.com/pardrugs/ We are one of the leading Manufacturer of various Inorganic Molecules such as-Magnesium Hydroxide, Aluminium Hydroxide, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etc. About Us Par Drugs & Chemicals Private Limited incorporated in the year 1982 and proved its competency as the known Manufacturer of various Inorganice Molecules such as- Magnesium Hydroxide, Aluminium Hydroxide, Magnesium Trisilicate, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etcs. Our products stand high in terms of quality and low whereas price is concerned. Mr. F. V. Savani (Marketing Director) has enabled us to gain prominent position in industry. He ensures that the customer’s needs are efficiently fulfilled in an appropriate manner and they are served as per their demands. We do not compromises in terms of quality of our range and ensure that the customers are served accordingly. Our team ensures that products are manufactured in confirmation with the specific quality standards. Packaging of our range is done carefully so that products may reach the clients end in safe manner. Regular training sessions keep our employees aware of the changes taking place in industry and ensure that they also perform accordingly. Our well-equipped infrastructure has enabled us to carry our business operations in smooth and efficient manner. We have efficiently segregated
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease
    International Journal of Molecular Sciences Review Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease Michiel Van Bulck 1,2 , Ana Sierra-Magro 1,2, Jesus Alarcon-Gil 1, Ana Perez-Castillo 1,2 and Jose A. Morales-Garcia 1,2,3,* 1 Instituto de Investigaciones Biomédicas (CSIC-UAM), Arturo Duperier, 4. 28029 Madrid, Spain; [email protected] (M.V.B.); [email protected] (A.S.-M.); [email protected] (J.A.-G.); [email protected] (A.P.-C.) 2 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Valderrebollo, 5, 28031 Madrid, Spain 3 Departamento de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, 28040 Madrid, Spain * Correspondence: [email protected] Received: 31 December 2018; Accepted: 3 February 2019; Published: 8 February 2019 Abstract: Neurodegenerative disorders affect around one billion people worldwide. They can arise from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer’s and Parkinson’s diseases. A progressive neurodegenerative process and neuroinflammation occur, and no current therapies can prevent, slow, or halt disease progression. To date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. Therefore, early diagnosis and the discovery of new targets and novel therapies are of upmost importance. Neurodegenerative diseases, like in other age-related disorders, the progression of pathology begins many years before the onset of symptoms. Many efforts in this field have led to the conclusion that exits some similar events among these diseases that can explain why the aging brain is so vulnerable to suffer neurodegenerative diseases.
    [Show full text]
  • The Comparison of the Effect Between Alginate-Based Raft-Forming Liquid and Alginate Liquid on Gastroesophageal Reflux Disease and Gastric Ulcer in Rats
    Online - 2455-3891 Vol 10, Issue 12, 2017 Print - 0974-2441 Research Article THE COMPARISON OF THE EFFECT BETWEEN ALGINATE-BASED RAFT-FORMING LIQUID AND ALGINATE LIQUID ON GASTROESOPHAGEAL REFLUX DISEASE AND GASTRIC ULCER IN RATS HAKIM BANGUN1*, ANAYANTI ARIANTO1, RIRIN ASTYA1, GONTAR A SIREGAR2 1Department of Pharmaceutical Technology, Faculty of Pharmacy, Nanomedicine Center, University of Sumatera Utara, Jl. Tri Dharma No. 5, Kampus USU, Medan, Indonesia. 2Department of Internal Medicine, Faculty of Medicine, University of Sumatera Utara, Jl Dr. T. Mansyur No. 5, Kampus USU, Medan, Indonesia. Email: [email protected] Received: 04 July 2017, Revised and Accepted: 16 August 2017 ABSTRACT Objective: The objective of the study was to compare the effect between alginate (Alg)-based raft-forming and Alg liquid on healing gastroesophageal reflux disease (GERD) and gastric ulcer in rats. Methods: Each of the 18 fasted rats was given 1 ml acidified pepsin. Then, rats were divided into three groups. Each group consisted of six rats. Group 1 (negative control) was orally given 1 ml distilled water, Group 2 was given 1 ml Alg-based raft-forming liquid, and Group 3 was given 1 ml Alg liquid. Then, the abdomen of rats was incised under anesthesia with ketamine, and then both their pylorus and the forestomach were ligated to form gastric reflux. After 4 hrs, all rats were killed with chloroform and their esophagus and stomach were examined macroscopically and microscopically (histopathology). Results: On macroscopic observation, all of the Group 1 rats (negative control) showed esophageal lesions and gastric lesions. Four rats of Group 2 (given Alg-based raft-forming) showed no esophageal lesion and two more rats showed a slight lesion, but all of the tested rats showed gastric lesions.
    [Show full text]
  • RAFT FORMING SYSTEM a REVIEW Bhavsar Dhaval Niranjanbhai*, Varde Neha Mahendrakumar, C
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Journal of Drug Delivery and Therapeutics (JDDT) Bhavsar et al Journal of Drug Delivery & Therapeutics; 2012, 2(5), 123-128 123 Available online at http://jddtonline.info REVIEW ARTICLE ADVANCES IN GRDDS: RAFT FORMING SYSTEM A REVIEW Bhavsar Dhaval Niranjanbhai*, Varde Neha Mahendrakumar, C. Sini Surendran, Shah Viral H, Upadhyay UM Dept. of pharmaceutics, Sigma Institute of Pharmacy, Bakrol, Vadodara(Gujarat), India *Corresponding Author’s Ph: +91-9725512814, Email id: [email protected] Received 06 June 2012; Review Completed 26 Aug 2012; Accepted 26 Aug 2012, Available online 15 Sep 2012 ABSTRACT: In recent years several advancements has been made in research and development of Gastro retentive drug delivery system to overcome the drawback of non-site specificity when drug administered orally. In order to understand various physiological difficulties to achieve gastric retention, we have summarized important factors controlling gastric retention time. We have reviewed various gastro retentive approaches designed and developed until now i.e. floating drug dosage systems (FDDS), swelling or expanding systems, mucoadhesive systems, high density system, Raft forming system, magnetic systems. Among these systems, the review summarizes the special focus on raft forming approach which comes under floating drug delivery system. Raft system incorporates alginate gels which have carbonate components react with gastric acid causes bubbles and this enables floating. Finally, Evaluation, advantages, disadvantages, future potential and marketed preparation of raft forming approach in gastro retentive drug delivery systems were covered. Key words-Advances in GRDDS, Raft forming system, alginic acid, gaviscon, INTRODUCTION: Conventional oral delivery is widely used in 4) Drugs with a narrow window of absorption E.g.
    [Show full text]
  • Therapeutic and Prophylactic Use of Oral, Low-Dose Ifns in Species of Veterinary Interest: Back to the Future
    veterinary sciences Review Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future Sara Frazzini 1 , Federica Riva 2,* and Massimo Amadori 3 1 Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy; [email protected] 2 Dipartimento di Medicina Veterinaria, Università degli Studi di Milano, 26900 Lodi, Italy 3 Rete Nazionale di Immunologia Veterinaria, 25125 Brescia, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0250334519 Abstract: Cytokines are important molecules that orchestrate the immune response. Given their role, cytokines have been explored as drugs in immunotherapy in the fight against different pathological conditions such as bacterial and viral infections, autoimmune diseases, transplantation and cancer. One of the problems related to their administration consists in the definition of the correct dose to avoid severe side effects. In the 70s and 80s different studies demonstrated the efficacy of cytokines in veterinary medicine, but soon the investigations were abandoned in favor of more profitable drugs such as antibiotics. Recently, the World Health Organization has deeply discouraged the use of antibiotics in order to reduce the spread of multi-drug resistant microorganisms. In this respect, the use of cytokines to prevent or ameliorate infectious diseases has been highlighted, and several studies show the potential of their use in therapy and prophylaxis also in the veterinary field. In this review we aim to review the principles of cytokine treatments, mainly IFNs, and to update the experiences encountered in animals. Keywords: veterinary immunotherapy; cytokines; IFN; low dose treatment; oral treatment Citation: Frazzini, S.; Riva, F.; Amadori, M.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Afelimomab (Rinn) Ic Medicines Under the Following Names: Adonis V
    2248 Supplementary Drugs and Other Substances Adiphenine Hydrochloride (USAN, rINNM) Adrenalone Hydrochloride (pINNM) ⊗ Uses. The use of aesculus has been reviewed;1,2 although there is some evidence suggesting benefit in chronic venous insuffi- Adiphénine, Chlorhydrate d’; Adiphenini Hydrochloridum; Adrénalone, Chlorhydrate d’; Adrenaloni Hydrochloridum; ciency, more rigorous studies are needed.2 Cloridrato de Adifenina; Hidrocloruro de adifenina; NSC- Adrenalonu chlorowodorek; Hidrocloruro de adrenalona. 1. Sirtori CR. Aescin: pharmacology, pharmacokinetics and thera- 129224; Spasmolytine. Адреналона Гидрохлорид peutic profile. Pharmacol Res 2001; 44: 183–93. Адифенина Гидрохлорид C H NO ,HCl = 217.6. 2. Pittler MH, Ernst E. Horse chestnut seed extract for chronic ve- 9 11 3 nous insufficiency. Available in The Cochrane Database of Sys- C20H25NO2,HCl = 347.9. CAS — 62-13-5. tematic Reviews; Issue 1. Chichester: John Wiley; 2006 (ac- CAS — 50-42-0. ATC — A01AD06; B02BC05. cessed 31/03/06). ATC Vet — QA01AD06; QB02BC05. Profile Preparations Adiphenine and adiphenine hydrochloride have been used as Profile Proprietary Preparations (details are given in Part 3) antispasmodics. Adrenalone hydrochloride is used as a local haemostatic and va- Arg.: Grafic Retard; Herbaccion Venotonico; Nadem; Venastat; Venostasin; soconstrictor. It has also been used with adrenaline in eye drops Austria: Aesculaforce; Provenen; Reparil; Venosin; Venostasin; Belg.: Preparations for glaucoma. Reparil; Veinofytol; Venoplant; Braz.: Phytovein; Reparil; Varilise;
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]